SKK
SRRA

Shepherd Kaplan Krochuk’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-950
Closed -$58K – 277
2017
Q1 		$58K Buy
+950
New +$55.2K 0.03% 239

Other funds holding SRRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Shepherd Kaplan Krochuk's SRRA Position: Q2 2017 in Review

Shepherd Kaplan Krochuk sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2017, closing a stake of 950 shares — an estimated $58K sold.

Shepherd Kaplan Krochuk first reported a position in SRRA in Q1 2017 and held it in 1 quarter. The position peaked at $58K in Q1 2017. 40 funds tracked by Wall St. Rank hold SRRA as of Q2 2017.

  • Shepherd Kaplan Krochuk reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 950 Sierra Oncology, Inc. Common Stock shares in Q2 2017, an estimated $58K.
  • Shepherd Kaplan Krochuk first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Shepherd Kaplan Krochuk's Sierra Oncology, Inc. Common Stock position peaked at $58K in Q1 2017.
  • 40 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2017.

Based on Shepherd Kaplan Krochuk's 13F filing for Q2 2017, filed 10 Aug 2017.